The hepatitis B rivalry between BMS and Gilead will be continued in the hepatitis C market

The BMS-Gilead competitive composition, continued in the chronic hepatitis B treatment market, will revive even in the chronic hepatitis C treatment market.

Recently, BMS has made aggressive behaviors, such as the strategy to reduce prices, to build its position in the domestic chronic hepatitis C treatment market.

According to the partial revision for the ‘Drug Insurance Benefit List and Cei...